阿法罗定，一种α-2拮抗剂，用于治疗进行性核上性麻痹。
Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.
作者信息
Rascol O, Sieradzan K, Peyro-Saint-Paul H, Thalamas C, Brefel-Courbon C, Senard J M, Ladure P, Montastruc J L, Lees A
机构信息
Department of Clinical Pharmacology, University Hospital, Toulouse, France.
出版信息
Mov Disord. 1998 Jul;13(4):673-6. doi: 10.1002/mds.870130411.
We have tested, in a prospective randomized, double-blind, placebo-controlled, crossover, 12-week study, the effects of 2 mg efaroxan, a potent alpha-2 antagonist, given three times per day to 14 patients with progressive supranuclear palsy. Efaroxan did not induce any significant change on any motor assessment criteria. The present data do not confirm the assumption that the blockade of alpha-2 receptors might be a useful pharmacologic strategy to improve patients with progressive supranuclear palsy.
在一项前瞻性随机、双盲、安慰剂对照、交叉的12周研究中，我们对14例进行性核上性麻痹患者每天三次给予2毫克强效α-2拮抗剂依发罗新，测试其效果。依发罗新在任何运动评估标准上均未引起任何显著变化。目前的数据并未证实α-2受体阻滞可能是改善进行性核上性麻痹患者的一种有用药理学策略这一假设。
Zotero 插件